What distinguishes VISTA from checkpoint molecules such as PD-1 and CTLA-4 is where it acts and how it is deployed. In many human malignancies, VISTA is preferentially enriched not on tumor cells themselves but on the innate immune cells that populate the tumor microenvironment, including tumor-associated macrophages, myeloid-derived suppressor cells and dendritic cells. This compartment-specific distribution matters because these myeloid populations orchestrate much of the immune suppression that characterizes so-called cold tumors. When VISTA is abundant on these cells, the result is suppressive myeloid differentiation, impaired antigen presentation, altered inflammatory cytokine programs and, ultimately, T-cell dysfunction and immune exclusion, the physical and functional exclusion of cytotoxic T lymphocytes from the tumor bed.

The structural biology of VISTA helps explain its unusual behavior. Like PD-L1, it belongs to the B7 family of immunoregulatory molecules, but it possesses distinctive features, including an acidic pH-selective binding mode. Landmark work published in Nature in 2019 demonstrated that VISTA functions as an acidic pH-selective ligand for PSGL-1, meaning its suppressive signaling is most active in the hypoxic, lactate-rich, acidic conditions that prevail inside solid tumors. This pH dependence effectively arms VISTA precisely where tumors are most aggressive and where other therapies struggle, and it may underlie the molecule’s contribution to resistance against PD-1 and CTLA-4 blockade in selected settings.

The receptor web surrounding VISTA extends well beyond PSGL-1. Subsequent studies have identified additional binding partners, including VSIG-3, which inhibits human T-cell function upon engagement, galectin-9, which cooperates with VISTA to suppress cytotoxic T lymphocyte activity, and LRIG1, which engages VISTA on dendritic cells and impairs tumor-specific CD8-positive T-cell responses. A recent study also revealed that a four-amino-acid intracellular motif of VISTA can block growth receptor signaling within cancer cells themselves, indicating that the molecule can exert tumor-intrinsic effects in addition to its immunoregulatory ones. Which of these ligand interactions dominates in living tumors remains an open question and one of the key unresolved issues highlighted by the review authors.

Evidence from preclinical models has been particularly revealing about the myeloid dimension. Research published in Cancer Immunol Res showed that VISTA controls antitumor immunity by regulating myeloid cell-mediated inflammation and immunosuppression, while a 2024 study in Cell Reports demonstrated that VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells through STAT3- and polyamine-dependent mechanisms. Hypoxia itself induces VISTA expression on myeloid-derived suppressor cells, amplifying their suppressive function. Work on tumor-associated macrophages has shown that VISTA drives these cells toward a pro-tumoral phenotype that promotes cancer cell phagocytosis while down-regulating T-cell responses, and that targeting a conserved population of TIM3-positive, VISTA-positive macrophages can overcome resistance to cancer immunotherapy.

The clinical relevance of this biology is increasingly documented across tumor types. In prostate cancer, VISTA expression was found to increase after ipilimumab therapy, positioning it as a mechanism of adaptive resistance. Comparative analyses of melanoma and pancreatic cancer identified VISTA as a potential target in the notoriously immunotherapy-resistant pancreatic setting, and elevated VISTA has been reported in gastric and colorectal carcinomas, oral squamous cell carcinoma, cervical carcinoma and non-small cell lung cancer. In metastatic melanoma, VISTA upregulation has been linked to acquired resistance to anti-PD-1 therapy. Intriguingly, the prognostic picture is not uniform: in triple-negative breast cancer, VISTA expression on immune cells correlated with favorable outcome, underscoring the review’s central argument that cellular source and spatial localization determine the biological and prognostic meaning of VISTA measurements.

Therapeutic strategies targeting VISTA have advanced into early clinical testing. The oral small-molecule inhibitor CA-170, derived from a PD-1 sequence, exhibited preclinical antitumor efficacy, although debate persists about its precise molecular targets. More refined approaches include KVA12123, a highly potent anti-VISTA antibody described as promising against poorly immunogenic tumors and currently in phase 1/2 testing alone and in combination with pembrolizumab in patients with advanced solid tumors, and HMBD-002, an IgG4 monoclonal antibody evaluated in a first-in-human phase 1 trial. A pH-selective antibody termed SNS-101 has been engineered to activate preferentially in the acidic tumor microenvironment, enhancing PD-1 pathway responses while limiting systemic exposure. Rationally designed antibodies that blockade the C-C’ loop region of VISTA have been shown to reverse immune suppression and remodel the immune microenvironment in an Fc-independent manner.

Combination approaches reflect the conviction that VISTA operates in parallel to, rather than downstream of, classical checkpoints. Bifunctional small molecules simultaneously targeting PD-L1 and VISTA have shown favorable pharmacokinetics in preclinical development, dual silencing of tumor-intrinsic VISTA and CTLA-4 has stimulated T-cell mediated responses in breast cancer models, and VISTA blockade has been shown to enhance the efficacy of radiotherapy in murine melanoma and adenocarcinoma models. Nanoparticle-based delivery systems targeting VISTA have induced potent antitumor immunity in preclinical studies, and chemotherapy itself has been shown to induce VISTA expression in tumor cells via HIF-2alpha, suggesting that sequencing VISTA-directed therapy with cytotoxic treatment could be clinically important.

Technological advances are reshaping how researchers interrogate VISTA biology. Spatial transcriptomics, multiplexed imaging platforms such as CODEX and imaging mass cytometry now allow investigators to map VISTA expression at single-cell resolution within intact tissue architecture, addressing precisely the questions of cellular source and spatial localization that the review identifies as central. Such compartment-resolved analysis may improve prognostic interpretation, biomarker development and patient selection for VISTA-directed therapies, moving the field beyond simple expression quantification toward a functional understanding of where, when and in whom the pathway matters.

The reviewers conclude that VISTA should be regarded as a dynamically regulated, myeloid-centered checkpoint axis rather than a redundant inhibitory receptor, with translational relevance concentrated in checkpoint-refractory and immune-excluded tumors. Whether early pharmacodynamic evidence of target engagement will convert into durable clinical benefit remains the decisive unanswered question, but as combination trials mature and spatial profiling sharpens patient stratification, VISTA is emerging as one of the most compelling next-generation targets in cancer immunotherapy, potentially unlocking treatment for the many patients whom PD-1 and CTLA-4 blockade have so far failed.

Subject of Research: VISTA immune checkpoint biology in myeloid cells and its therapeutic targeting in cancer

Article Title: VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications

Article References: Tekiner, S., Karataş, R. B., Alras, Y., Zıkşahna, K., Merdan, S., & Ihlamur, M. (2026). VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications. Medical Oncology, 43(10), Article 280. https://doi.org/10.1007/s12032-026-03416-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03416-1

Keywords: VISTA, VSIR, immune checkpoint, myeloid cells, tumor microenvironment, tumor-associated macrophages, myeloid-derived suppressor cells, cancer immunotherapy, checkpoint resistance, PSGL-1, acidic pH, antibody therapy

The central finding is one of contrast. When the researchers exposed a global collection of 411 Z. tritici strains to salicylic acid, a key plant defense hormone, fungal growth in vitro was markedly inhibited. Acidic pH, by comparison, actually promoted growth, demonstrating that the simulated host-associated environments exert opposing effects on pathogen proliferation rather than a uniform stress. This distinction matters because it suggests the fungus does not face a single hostile chemical landscape during infection but a mosaic of pressures, some suppressive and some apparently permissive, each demanding its own tailored response.

At the level of gene expression, the picture became even more nuanced. The team found that acidic pH and oxidative stress, induced by hydrogen peroxide, triggered the strongest and most similar transcriptional responses, reshaping broad swaths of the fungal transcriptome. Salicylic acid, however, elicited a distinctly different transcriptional program, while gibberellic acid, a plant hormone associated with growth and development, caused only limited changes in gene expression. In other words, the fungus discriminates finely between the chemical cues it encounters, mounting a heavy transcriptional reaction to acidity and reactive oxygen species while treating the gibberellin signal as a relatively minor perturbation.

Despite the largely condition-specific nature of these responses, the analysis uncovered a common thread. Across the different treatments, the researchers observed overlapping enrichment of genes involved in transport functions and redox-related processes. Membrane transporters and redox machinery appear to form a shared backbone of fungal adaptation, deployed regardless of the specific stress encountered. This convergence hints at an evolutionary logic: whatever the host throws at the pathogen, moving molecules across membranes and managing cellular oxidation states are universal requirements for survival, so the fungus maintains and recruits these systems across contexts while layering more specialized responses on top.

The differential expression results themselves were strikingly environment-specific. Only a small core of nine differentially expressed genes was shared across four of the five environmental comparisons examined, and the Jaccard similarity between gene sets from different treatments was low. Functional categorization of the environment-specific genes revealed that each condition recruited its own repertoire of up- and down-regulated functions, from cell wall remodeling to proteostasis. This modular organization means that blocking a single adaptive pathway is unlikely to cripple the pathogen’s overall resilience, a sobering implication for breeding and fungicide strategies that target one mechanism at a time.

To move beyond gene expression and identify the underlying genetic determinants, the team turned to a k-mer-based genome-wide association study across their 411-strain panel. Rather than relying on predefined SNP markers, k-mer GWAS scans the entire genome sequence for short DNA words whose presence correlates with phenotypic variation, an approach well suited to a pathogen with substantial standing genetic diversity. The analysis identified five candidate loci associated with growth under acidic pH, gibberellic acid and salicylic acid, four of which were specific to individual growth conditions. This condition-specific genetic architecture mirrors the transcriptional pattern, reinforcing the conclusion that adaptation to each host-like environment is governed largely by distinct sets of genes.

The candidate loci were not anonymous stretches of DNA. They colocalized with genes implicated in biologically meaningful processes: cell wall remodeling, nitrogen metabolite regulation, proteostasis and ubiquitin-related protein degradation pathways. Cell wall remodeling is an intuitively plausible adaptation, since the fungal wall is the first line of contact with acidic and oxidative insults. Nitrogen metabolite regulation suggests the fungus reprograms nutrient acquisition under stress, while proteostasis and ubiquitin pathways point to the need to maintain protein quality control when cellular machinery is damaged. Together these associations provide a first genomic map of how natural variation in Z. tritici underpins tolerance of host-derived stresses.

The phenotyping effort underpinning the study was itself an achievement in scale and rigor. Growth of each of the 411 strains was quantified across control and treatment conditions using seven derived variables, including growth rate, inflection time, carrying capacity estimated from logistic regression, spore concentrations at 48, 96 and 144 hours post-inoculation obtained by locally weighted polynomial regression, and an empirical area under the growth curve. Sensitivity to each simulated host environment was then calculated as the ratio of treatment to control area under the curve. Linear mixed-effects models with Tukey post-hoc comparisons revealed significant differences both among environments and among previously defined genetic clusters of the pathogen, indicating that adaptation is shaped not only by immediate physiological responses but also by population history and lineage-specific variation.

Why does this matter beyond the laboratory? Septoria tritici blotch remains one of the most economically damaging wheat diseases worldwide, and control relies heavily on fungicides and resistant cultivars, both of which the pathogen has repeatedly circumvented. By showing that Z. tritici possesses a dual arsenal, a set of shared core responses plus a library of environment-specific transcriptional and genetic modules, the study suggests that host-imposed stresses such as acidity, salicylic acid and oxidative bursts exert selection on the pathogen during infection. Understanding which loci and pathways confer tolerance could inform breeding strategies that stack multiple forms of environmental hostility inside the plant, making the apoplast a more formidable and less predictable battlefield for the fungus.

The research also contributes methodologically. The integration of k-mer GWAS with RNA sequencing across matched control and treatment conditions offers a template for dissecting quantitative traits in other filamentous pathogens, where reference-based SNP calling can miss structural and accessory-genome variation. The authors acknowledge that their assays simulate individual host-associated factors in vitro rather than the full complexity of living wheat tissue, and that the accepted-manuscript version of the paper is subject to final editorial edits. Even so, the convergence of phenotypic, transcriptomic and population-genomic evidence makes a compelling case that Z. tritici’s success as a pathogen rests on its capacity to tailor responses to each chemical facet of its host, combining shared resilience mechanisms with a condition-specific toolkit that evolution has assembled across a diverse global population.

Subject of Research: Transcriptional and genetic mechanisms of Zymoseptoria tritici adaptation to simulated host-associated environments

Article Title: Contrasting transcriptional responses and genetic determinants underlie Zymoseptoria tritici adaptation mechanisms to simulated host-associated environments

Article References: Miñana-Posada, S., Feurtey, A., McDonald, B. A., & Lorrain, C. (2026). Contrasting transcriptional responses and genetic determinants underlie Zymoseptoria tritici adaptation mechanisms to simulated host-associated environments. BMC Genomics. https://doi.org/10.1186/s12864-026-13300-x

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13300-x

Keywords: Zymoseptoria tritici, wheat pathogen, transcriptomics, genome-wide association study, k-mer GWAS, salicylic acid, oxidative stress, acidic pH, gibberellic acid, fungal genetics, plant-pathogen interactions, BMC Genomics